Dissemination & Policy Core Since CHERISH was established in 2015, economic research to inform policymakers and the public regarding treatments for substance use disorder, HCV, and HIV has only increased in importance. Substance use disorder has claimed the attention of mass media and policy makers, but large gaps remain in the translation and use of evidence. Although economic evidence can help bridge this gap by addressing costs, tradeoffs, and sustainability of best practices, research must address stakeholders? priorities to have policy and public health impact. Findings must be communicated effectively to the right audience, in the right format, at the right time. To meet these needs, the CHERISH Dissemination & Policy Core uses the tools of dissemination science to assess, facilitate, and build researchers? and stakeholders? capacities to exchange knowledge. In this renewal, the Core will expand its role as a knowledge broker and translation capacity builder connecting researchers and stakeholders, and we will directly assist research teams. Our affiliation with the Leonard Davis Institute of Health Economics at the University of Pennsylvania brings deep expertise in translation and dissemination of health policy research ? including engaging stakeholders and researchers in settings that build expertise in dissemination science theory and practice, promote information exchange, and leverage clinical experience in treatment of SUD, HCV, and HIV. The overall aim of CHERISH (Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV) is to develop and disseminate economic evidence that informs substance use disorder policy and HCV and HIV care of people who use substances. In this renewal period we will expand our focus to outcome and implementation research conducted at the individual, system, and community-levels with the following specific aims: 1) to engage stakeholders and health economics researchers in information exchange and translate health economic research results addressing substance use disorder treatment policy and HCV and HIV care for people who use substances, and 2) to build the dissemination science knowledge base in substance use disorder policy and HCV and HIV care by developing and implementing training on best practices for stakeholder engagement and communication of relevant economic methodologies, and by conducting relevant dissemination science research. We will translate research results for target policy audiences, with a focus on state and local policymakers and influencers. Our dissemination science activities will assist research teams, incorporating findings from our stakeholder needs assessment and face-to-face engagement with decision makers and their advisors including members of our Policy Advisory Board. We will develop, pilot, and implement a curriculum for substance use health economics and health services researchers to improve knowledge translation capacity. After the curriculum is established, we will host workshops at national meetings to introduce and refine the curriculum.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
2P30DA040500-06A1
Application #
10079949
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
2025-04-30
Budget Start
2020-07-01
Budget End
2021-04-30
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Type
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Freiman, J Morgan; Jacobson, Karen R; Muyindike, Winnie R et al. (2018) Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr 77:405-412
Kapadia, Shashi N; Jeng, Philip J; Schackman, Bruce R et al. (2018) State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals. Clin Infect Dis 66:1618-1620
Friedmann, Peter D; Wilson, Donna; Nunes, Edward V et al. (2018) Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder? J Subst Abuse Treat 85:61-65
Kapadia, Shashi N; Wu, Chunyuan; Mayer, Kenneth H et al. (2018) No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. PLoS One 13:e0206577
McCollister, Kathryn E; Yang, Xuan; Murphy, Sean M et al. (2018) Criminal justice measures for economic data harmonization in substance use disorder research. Health Justice 6:17
Chen, Donna T; Ko, Tomohiro M; Allen, Ashleigh A et al. (2018) Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision. J Empir Res Hum Res Ethics 13:160-172
Graves, Rachel L; Andreyeva, Elena; Perrone, Jeanmarie et al. (2018) Naloxone Availability and Pharmacy Staff Knowledge of Standing Order for Naloxone in Pennsylvania Pharmacies. J Addict Med :
Liang, Di; Bao, Yuhua; Wallace, Mark et al. (2018) Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014. Addiction 113:2060-2070
Graves, Rachel L; Tufts, Christopher; Meisel, Zachary F et al. (2018) Opioid Discussion in the Twittersphere. Subst Use Misuse 53:2132-2139
Schackman, Bruce R; Gutkind, Sarah; Morgan, Jake R et al. (2018) Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. Drug Alcohol Depend 185:411-420

Showing the most recent 10 out of 93 publications